Literature DB >> 23239916

Utility of faecal calprotectin analysis in adult inflammatory bowel disease.

Lyn A Smith1, Daniel R Gaya.   

Abstract

The inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, are chronic relapsing, remitting disorders. Diagnosis, along with assessment of disease activity and prognosis present challenges to managing clinicians. Faecal biomarkers, such as faecal calprotectin, are a non-invasive method which can be used to aid these decisions. Calprotectin is a calcium and zinc binding protein found in the cytosol of human neutrophils and macrophages. It is released extracellularly in times of cell stress or damage and can be detected within faeces and thus can be used as a sensitive marker of intestinal inflammation. Faecal calprotectin has been shown to be useful in the diagnosis of IBD, correlates with mucosal disease activity and can help to predict response to treatment or relapse. With growing evidence supporting its use, over the last decade this faecal biomarker has significantly changed the way IBD is managed.

Entities:  

Keywords:  Crohn’s disease; Faecal biomarker; Faecal calprotectin; Inflammatory bowel disease; Ulcerative colitis

Mesh:

Substances:

Year:  2012        PMID: 23239916      PMCID: PMC3520167          DOI: 10.3748/wjg.v18.i46.6782

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  71 in total

1.  Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-Effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study.

Authors:  Liselotte Kok; Sjoerd G Elias; Ben J M Witteman; Jelle G Goedhard; Jean W M Muris; Karel G M Moons; Niek J de Wit
Journal:  Clin Chem       Date:  2012-03-09       Impact factor: 8.327

2.  Evaluation of the Quantum Blue® rapid test for faecal calprotectin.

Authors:  Julie Wassell; Michael Wallage; Ella Brewer
Journal:  Ann Clin Biochem       Date:  2011-09-19       Impact factor: 2.057

3.  Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.

Authors:  D Laharie; S Mesli; F El Hajbi; E Chabrun; E Chanteloup; M Capdepont; S Razaire; V de Lédinghen; F Zerbib
Journal:  Aliment Pharmacol Ther       Date:  2011-06-14       Impact factor: 8.171

4.  Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.

Authors:  Edouard Louis; Jean-Yves Mary; Gwenola Vernier-Massouille; Jean-Charles Grimaud; Yoram Bouhnik; David Laharie; Jean-Louis Dupas; Hélène Pillant; Laurence Picon; Michel Veyrac; Mathurin Flamant; Guillaume Savoye; Raymond Jian; Martine Devos; Raphaël Porcher; Gilles Paintaud; Eric Piver; Jean-Frédéric Colombel; Marc Lemann
Journal:  Gastroenterology       Date:  2011-09-22       Impact factor: 22.682

5.  Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.

Authors:  Petr Ricanek; Stephan Brackmann; Gøri Perminow; Lars G Lyckander; Jon Sponheim; Oyvind Holme; Ole Høie; Andreas Rydning; Morten H Vatn
Journal:  Scand J Gastroenterol       Date:  2011-05-30       Impact factor: 2.423

6.  Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?

Authors:  Valle García-Sánchez; Eva Iglesias-Flores; Raúl González; Javier P Gisbert; José María Gallardo-Valverde; Angel González-Galilea; Antonio Naranjo-Rodríguez; Juan F de Dios-Vega; Jordi Muntané; Federico Gómez-Camacho
Journal:  J Crohns Colitis       Date:  2009-12-02       Impact factor: 9.071

7.  Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy.

Authors:  Taina Sipponen; Johanna Haapamäki; Erkki Savilahti; Henrik Alfthan; Esa Hämäläinen; Henna Rautiainen; Jari Koskenpato; Hannu Nuutinen; Martti Färkkilä
Journal:  Scand J Gastroenterol       Date:  2012-04-23       Impact factor: 2.423

8.  Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.

Authors:  Michael J Sydora; Beate C Sydora; Richard N Fedorak
Journal:  J Crohns Colitis       Date:  2011-09-07       Impact factor: 9.071

9.  Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes.

Authors:  Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Michael Trummler; Pietro Renzulli; Frank Seibold
Journal:  Inflamm Bowel Dis       Date:  2009-05-21       Impact factor: 5.325

Review 10.  Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.

Authors:  Patrick F van Rheenen; Els Van de Vijver; Vaclav Fidler
Journal:  BMJ       Date:  2010-07-15
View more
  20 in total

1.  The Use of Fecal Calprotectin in Inflammatory Bowel Disease.

Authors:  Ingvar Bjarnason
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-01

2.  Fecal calprotectin and α1-antitrypsin dynamics in gastrointestinal GvHD.

Authors:  A O'Meara; N Kapel; A Xhaard; F Sicre de Fontbrune; D Manéné; N Dhedin; R P de Latour; G Socié; M Robin
Journal:  Bone Marrow Transplant       Date:  2015-05-11       Impact factor: 5.483

Review 3.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

4.  Noninvasive Markers of Disease Activity in Inflammatory Bowel Disease.

Authors:  Raluca Vrabie; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

5.  Nickel Sequestration by the Host-Defense Protein Human Calprotectin.

Authors:  Toshiki G Nakashige; Emily M Zygiel; Catherine L Drennan; Elizabeth M Nolan
Journal:  J Am Chem Soc       Date:  2017-06-22       Impact factor: 15.419

Review 6.  Disease monitoring in inflammatory bowel disease.

Authors:  Shannon Chang; Lisa Malter; David Hudesman
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

7.  Assessment of the usefulness of imaging studies and biomarkers in the activity of Crohn's disease.

Authors:  Grażyna Piotrowicz; Agnieszka Klufczyńska; Piotr Banaszkiewicz; Łukasz Dorosz; Grażyna Rydzewska
Journal:  Prz Gastroenterol       Date:  2020-03-09

8.  The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding.

Authors:  Stephan R Vavricka; Henriette Heinrich; Simon Buetikofer; Flavia Breitenmoser; Emanuel Burri; Xiaoye Schneider-Yin; Jasmin Barman-Aksoezen; Luc Biedermann; Michael Scharl; Jonas Zeitz; Gerhard Rogler; Benjamin Misselwitz; Matthias Sauter
Journal:  United European Gastroenterol J       Date:  2018-05-28       Impact factor: 4.623

Review 9.  Biomarkers of Inflammation and Immune Function and Risk of Colorectal Cancer.

Authors:  Alicia Garcia-Anguita; Artemisia Kakourou; Konstantinos K Tsilidis
Journal:  Curr Colorectal Cancer Rep       Date:  2015

Review 10.  Biomarkers of inflammatory bowel disease.

Authors:  Yi Fengming; Wu Jianbing
Journal:  Dis Markers       Date:  2014-05-19       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.